Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Centre Hospitalier Universitaire Vaudois
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07263438CT.gov Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial | — | Recruiting | — | — | — |
NCT07538128CT.gov Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma | — | Recruiting | — | — | — |
NCT06069726CT.gov A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial | — | Recruiting | — | — | — |
NCT05423210CT.gov Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme | — | Recruiting | — | — | — |
NCT05039281CT.gov Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma | — | Recruiting | — | — | — |
NCT04729959CT.gov Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma | — | Active Not Recruiting | — | — | — |
NCT05023551CT.gov Study of DSP-0390 in Patients With Recurrent High-Grade Glioma | — | Active Not Recruiting | — | — | — |
NCT03673787CT.gov A Trial of Ipatasertib in Combination With Atezolizumab | — | Active Not Recruiting | — | — | — |
NCT03174197CT.gov Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Glioblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Atezolizumab (this asset) | Centre Hospitalier Universitaire Vaudois | P2 | B · 62 |
| Depatuxizumab Mafodotin | AbbVie | P3 | BB |
| Cintredekin Besudotox | INSYS Therapeutics Inc | P3 | BB |
| Camustine | Leland Metheny | P3 | BB |
| (+)-Vincristine | University of Cincinnati | P3 | BB |
| Irinotecan | University of Cincinnati | P3 | BB |
| Capecitabine | Northwell Health | P2 | BB |
| Lomustine | Telix Pharmaceuticals (Innovations) Pty Limited | P3 | BB |
| Carboplatin | Sichuan Honghe Biotechnology Co., Ltd. | P3 | BB |
+42 more in the Glioblastoma cohort
Other indications for Atezolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P2/3 | BB · 71 |
| Her2-Receptor Negative Breast Cancer | — | P2 | BB · 69 |
| Bladder Transitional Cell Carcinoma | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Atezolizumab in Glioblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/atezolizumab-glioblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →